Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi

National Committee for Clinical Laboratory Standards

Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736

Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000

Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 405

Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi

Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N., & Pfaller, M. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3623-3626.2003 · Cited by 370

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

Courtney, R., Wexler, D. B., Radwanski, E., Lim, J. M., & Laughlin, M. A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 328

In vitro susceptibilities of zygomycetes to conventional and new antifungals

Dannaoui, É. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 312

Experimental Pulmonary Aspergillosis Due toAspergillus terreus:Pathogenesis and Treatment of an Emerging Fungal Pathogen Resistant to Amphotericin B

Walsh, T. J., Petraitis, V., Petraitienė, R., Field‐Ridley, A., Sutton, D. A., Ghannoum, M. A., Sein, T., Schaufele, R. L., Peter, J., Bacher, J. D., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377210 · Cited by 252

Untitled work

(2003) · PubMed · Cited by 240

Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection

Denning, D. W. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.3.401 · Cited by 234

In Vitro Activities of New and Conventional Antifungal Agents against ClinicalScedosporiumIsolates

Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., Rodriquez-Tudela, J. L., Donnelly, J. P., Verweij, P. E., & the EUROFUNG Network (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.62-68.2002 · Cited by 232

Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum

Cuenca‐Estrella, M., Ruiz-Dı́ez, B., Martı́nez-Suárez, J. V., Monzón, A., & Rodrı́guez-Tudela, J. L. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.1.149 · Cited by 211

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem

Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174

Fusarium Infections in Immunocompromised Patients

Nucci, M., & Anaissie, E. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-07 · Cited by 979

Epidemiology of Invasive Mycoses in North America

Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901

Resistance to Antifungal Agents: Mechanisms and Clinical Impact

Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619

Melanized Fungi in Human Disease

Revankar, S. G., & Sutton, D. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-10 · Cited by 577

Changing epidemiology of systemic fungal infections

Richardson, M., & Lass-Flörl, C. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01978.x · Cited by 524

ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

Tortorano, A. M., Richardson, M. D., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E. M., Meletiadis, J., Pana, Z. D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 517

A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations

Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490

Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology

Hoenigl, M., Salmanton‐García, J., Walsh, T. J., Nucci, M., Neoh, C. F., Jenks, J. D., Lackner, M., Sprute, R., Al‐Hatmi, A. M. S., Bassetti, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30784-2 · Cited by 476

Pharmacokinetic/Pharmacodynamic Profile of Posaconazole

Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 452

Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents

Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi

Chowdhary, A., Meis, J. F. G. M., Guarro, J., de Hoog, S., Kathuria, S., Arendrup, M. C., Arıkan-Akdağlı, S., Akova, M., Boekhout, T., Caira, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12515 · Cited by 381

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing

Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Hu, B., Dzierzanowska, D., Климко, Н. Н., Letscher‐Bru, V., Lisalová, M., Muehlethaler, K., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370

Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285

In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents

Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., & Kusne, S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00452-07 · Cited by 284

Candida krusei , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005

Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiášová, S., Rinaldi, M. G., Barton, R., Veselov, A. V., & the Global Antifungal Surveillance Group (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01915-07 · Cited by 276

Fungal echinocandin resistance

Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267

Voriconazole in the treatment of fungal eye infections: a review of current literature

Hariprasad, S. M., Mieler, W. F., Lin, T. K., Sponsel, W. E., & Graybill, J. R. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.136515 · Cited by 265

Alternaria infections: laboratory diagnosis and relevant clinical features

Pastor, F., & Guarro, J. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02024.x · Cited by 241

Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

Cendejas‐Bueno, E., Kolecka, A., Alastruey‐Izquierdo, A., Theelen, B., Groenewald, M., Kostrzewa, M., Cuenca‐Estrella, M., Gómez‐López, A., & Boekhout, T. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.02248-12 · Cited by 234

Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods

Alastruey‐Izquierdo, A., Cuenca‐Estrella, M., Monzón, A., Mellado, E., & Rodríguez-Tudela, J. L. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn022 · Cited by 222

Non-neoformans Cryptococcal Infections: a Systematic Review

Khawcharoenporn, T., Apisarnthanarak, A., & Mundy, L. M. (2007) · Infection · doi:10.1007/s15010-007-6142-8 · Cited by 222

Exogenous Fungal Endophthalmitis: Microbiology and Clinical Outcomes

Wykoff, C. C., Flynn, H. W., Miller, D., Scott, I. U., & Alfonso, E. C. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.02.027 · Cited by 192

Comparison of the Vitek 2 Antifungal Susceptibility System with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest Techniques for In Vitro Detection of Antifungal Resistance in Yeast Isolates

Cuenca‐Estrella, M., Gómez‐López, A., Alastruey‐Izquierdo, A., Bernal‐Martínez, L., Cuesta, I., Buitrago, M. J., & Rodrı́guez-Tudela, J. L. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02316-09 · Cited by 172

Breaking the Mold

Riley, T. T., Muzny, C. A., Swiatlo, E., & Legendre, D. P. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016655425 · Cited by 166

Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

Lass‐Flörl, C., Mayr, A., Perkhofer, S., Hinterberger, G., Hausdorfer, J., Speth, C., & Fille, M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00662-08 · Cited by 151

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance

Fera, M. T., Camera, E. L., & Sarro, A. D. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.67 · Cited by 136

Posaconazole: An extended-spectrum triazole antifungal agent

SCHILLER, D., & Fung, H. B. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.015 · Cited by 135

Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole

Thompson, G. R., & Wiederhold, N. P. (2010) · Mycopathologia · doi:10.1007/s11046-010-9324-3 · Cited by 134

Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132

Variation in Susceptibility of Bloodstream Isolates ofCandida glabratato Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007

Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L. B., Tendolkar, S., Kroeger, J. S., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00946-09 · Cited by 128

In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of RareCandidaSpecies as Determined by CLSI Broth Microdilution Methods

Diekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Tendolkar, S., & Pfaller, M. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00942-09 · Cited by 125

Current antifungal treatment of fusariosis

Al‐Hatmi, A. M. S., Bonifáz, A., Ranque, S., de Hoog, S., Verweij, P. E., & Meis, J. F. G. M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.017 · Cited by 129

Multiplex Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification in Human Plasma of Fluconazole, Itraconazole, Hydroxyitraconazole, Posaconazole, Voriconazole, Voriconazole- N -Oxide, Anidulafungin, and Caspofungin

Decosterd, L. A., Rochat, B., Pesse, B., Mercier, T., Tissot, F., Widmer, N., Billé, J., Calandra, T., Zanolari, B., & Marchetti, O. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00404-10 · Cited by 122

Semi-national surveillance of fungaemia in Denmark 2004–2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility

Arendrup, M. C., Fuursted, K., Gahrn-Hansen, B., Schønheyder, H. C., Knudsen, J. D., Jensen, I., Bruun, B., Christensen, J. J., & Johansen, H. K. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01954.x · Cited by 120

In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species

Pfaller, M. A., Messer, S. A., Boyken, L. B., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00535-08 · Cited by 119

Scedosporium apiospermum infection after near‐drowning

Katragkou, A., Dotis, J., Kotsiou, M., Tamiolaki, M., & Roilides, E. (2007) · Mycoses · doi:10.1111/j.1439-0507.2007.01388.x · Cited by 118

Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005

Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ng, K. P., Colombo, A. L., Finquelievich, J. L., Barnes, R. A., & Wadula, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02122-07 · Cited by 105

Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex

Al‐Hatmi, A. M. S., van Diepeningen, A. D., Curfs-Breuker, I., de Hoog, S., & Meis, J. F. G. M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku505 · Cited by 107

Nebulized Liposomal Amphotericin B Prophylaxis for Aspergillus Infection in Lung Transplantation: Pharmacokinetics and Safety

Monforte, V., Ussetti, P., López, R. M., Gavaldà, J., Bravo, C., de Pablo, A., Pou, L., Pahissa, A., Morell, F., & Román, A. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.11.004 · Cited by 106

Epidemiology of invasive fungal infection

Castón, J. J., Rivero, A., & Torre‐Cisneros, J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70009-8 · Cited by 105

Use of Antifungal Combination Therapy: Agents, Order, and Timing

Johnson, M. D., & Perfect, J. R. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0018-6 · Cited by 103

Successful Treatment of Resistant Ocular Fusariosis With Posaconazole (SCH-56592)

Tu, E. Y., McCartney, D. L., Beatty, R. F., Springer, K. L., Levy, J., & Edward, D. P. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.10.048 · Cited by 101

Value of Serial Quantification of Fungal DNA by a Real-Time PCR-Based Technique for Early Diagnosis of Invasive Aspergillosis in Patients with Febrile Neutropenia

Cuenca‐Estrella, M., Meije, Y., Díaz‐Pedroche, C., Gómez‐López, A., Buitrago, M. J., Bernal‐Martínez, L., Grande, C., Juan, R. S., Lizasoaín, M., Rodrı́guez-Tudela, J. L., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01716-08 · Cited by 98

Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside

Cuenca‐Estrella, M. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12495 · Cited by 101

Accurate and Practical Identification of 20 Fusarium Species by Seven-Locus Sequence Analysis and Reverse Line Blot Hybridization, and an In Vitro Antifungal Susceptibility Study

Wang, H., Xiao, M., Kong, F., Chen, W., Dou, H., Sorrell, T. C., Li, R., & Xu, Y. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02415-10 · Cited by 92

Enfermedades Infecciosas y Microbiología Clínica

Viasus, D., Antón, A., Pumarola, T., & Carratalà, J. (2016) · Cited by 90

In Vitro Activities of 35 Double Combinations of Antifungal Agents against Scedosporium apiospermum and Scedosporium prolificans

Cuenca‐Estrella, M., Alastruey‐Izquierdo, A., Alcázar‐Fuoli, L., Bernal‐Martínez, L., Gómez‐López, A., Buitrago, M. J., Mellado, E., & Rodrı́guez-Tudela, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01160-07 · Cited by 85

Pathogenic factors inCandidabiofilm-related infectious diseases

Hirota, K., Yumoto, H., Bayarmagnai, S., Matsuo, T., Ichikawa, T., & Miyake, Y. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13330 · Cited by 85

Is Azole Resistance in Aspergillus fumigatus a Problem in Spain?

Escribano, P., Peláez, T., Muñóz, P., Bouza, E., & Guinea, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02487-12 · Cited by 85

Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed Spacers

Alastruey‐Izquierdo, A., Castelli, M. V., Cuesta, I., Monzón, A., Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01467-08 · Cited by 84

Pharmacologic therapy of mycotic keratitis

Sahay, P., Singhal, D., Nagpal, R., Maharana, P. K., Farid, M., Gelman, R. A., Sinha, R., Agarwal, T., Titiyal, J. S., & Sharma, N. (2019) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2019.02.007 · Cited by 83

In vitro activity of antifungals against Zygomycetes

Alastruey‐Izquierdo, A., Castelli, M. V., Cuesta, I., Zaragoza, Ó., Monzón, A., Mellado, E., & Rodríguez-Tudela, J. L. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02984.x · Cited by 83

Invasive Candidiasis: An Overview from Taiwan

Ruan, S., & Hsueh, P. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60091-7 · Cited by 85

Antifungal Susceptibility Testing of Fusarium: A Practical Approach

Al‐Hatmi, A. M. S., Curfs-Breuker, I., de Hoog, S., Meis, J. F. G. M., & Verweij, P. E. (2017) · Journal of Fungi · doi:10.3390/jof3020019 · Cited by 84

Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019

Jenks, J. D., Seidel, D., Cornely, O. A., Chen, S., van Hal, S., Kauffman, C. A., Miceli, M. H., Heinemann, M., Christner, M., Jover-Sáenz, A., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.01.012 · Cited by 80

In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

Perkhofer, S., Lechner, V., & Lass‐Flörl, C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01530-08 · Cited by 80

Epidemiology, Incidence and Risk Factors for Invasive Candidiasis in High-Risk Patients

Concia, E., Azzini, A. M., & Conti, M. (2009) · Drugs · doi:10.2165/11315500-000000000-00000 · Cited by 77

Alternaria Keratitis: Clinical Presentation and Resolution With Topical Fluconazole or Intrastromal Voriconazole and Topical Caspofungin

Tu, E. Y. (2008) · Cornea · doi:10.1097/ico.0b013e31818225f8 · Cited by 77

Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Ruhnke, M., Cornely, O. A., Schmidt‐Hieber, M., Alakel, N., Boell, B., Buchheidt, D., Christopeit, M., Hasenkamp, J., Heinz, W., Hentrich, M., et al. (2020) · Mycoses · doi:10.1111/myc.13082 · Cited by 76

Species Identification and Antifungal Susceptibility Patterns of Species Belonging to Aspergillus Section Nigri

Alcázar‐Fuoli, L., Mellado, E., Alastruey‐Izquierdo, A., Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00585-09 · Cited by 74

Overweight treated with energy restriction and a dietary fibre supplement: a 6-month randomized, double-blind, placebo-controlled trial.

Rigaud, D., Ryttig, K. R., Ángel, L., & Apfelbaum, M. (1990) · PubMed · Cited by 73

Novel antifungal agents: a patent review (2011 – present)

Castelli, M. V., Butassi, E., Monteiro, M. C., Svetaz, L. A., Vicente, F., & Zacchino, S. A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.876993 · Cited by 76

Invasive infections caused by Saprochaete capitata in patients with haematological malignancies: Report of five cases and review of the antifungal therapy

García‐Ruiz, J. C., López-Soria, L., Olazábal, I., Amutio, E., Arrieta-Aguirre, I., Benito, V. V., Pontón, J., & Moragues, M. D. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.02.004 · Cited by 71

Comparativein vitroactivities of posaconazole, voriconazole, itraconazole, and amphotericin B againstAspergillusandRhizopus, and synergy testing forRhizopus

Arıkan, S., Sancak, B., Alp, Ş., Hasçelik, G., & McNicholas, P. M. (2008) · Medical Mycology · doi:10.1080/13693780801975576 · Cited by 68

In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus : Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing

Lass‐Flörl, C., Alastruey‐Izquierdo, A., Cuenca‐Estrella, M., Perkhofer, S., & Rodrı́guez-Tudela, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00335-08 · Cited by 68

Identification of Pathogenic Rare Yeast Species in Clinical Samples: Comparison between Phenotypical and Molecular Methods

Cendejas‐Bueno, E., Gómez‐López, A., Mellado, E., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00336-10 · Cited by 67

Role for Fks1 in the Intrinsic Echinocandin Resistance of Fusarium solani as Evidenced by Hybrid Expression in Saccharomyces cerevisiae

Katiyar, S. K., & Edlind, T. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00020-09 · Cited by 69

Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro

Perkhofer, S., Locher, M., Cuenca‐Estrella, M., Rüchel, R., Würzner, R., Dierich, M. P., & Lass‐Flörl, C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00492-08 · Cited by 66

Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope ® registry

Jenks, J. D., Seidel, D., Cornely, O. A., Chen, W., van Hal, S. J., Kauffman, C. A., Miceli, M. H., Heinemann, M., Christner, M., Jover-Sáenz, A., et al. (2020) · Mycoses · doi:10.1111/myc.13067 · Cited by 63

Cryptococcosis: An Emerging Respiratory Mycosis

Huston, S. M., & Mody, C. H. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.006 · Cited by 65

Filamentous Fungi in Respiratory Infections. What Lies Beyond Aspergillosis and Mucormycosis?

Chowdhary, A., Agarwal, K., & Meis, J. F. G. M. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005491 · Cited by 63

EndogenousCandidaendophthalmitis

Sallam, A. B., Lynn, W. A., McCluskey, P., & Lightman, S. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.4.675 · Cited by 60

Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis

Badali, H., Bonifáz, A., Tapia, T. B., Vázquez‐González, D., Estrada-Aguilar, L., Oliveira, N. M. C., Filho, J. F. S., Guarro, J., Meis, J. F. G. M., & de Hoog, S. (2010) · Medical Mycology · doi:10.3109/13693780903471073 · Cited by 61

Antifúngicos em infecções oculares: drogas e vias de administração

Muller, G. G., Kara-Júnior, N., & de Castro, R. S. (2013) · Revista Brasileira de Oftalmologia · doi:10.1590/s0034-72802013000200014 · Cited by 60

BreakthroughSaprochaete capitatainfections in patients receiving echinocandins: case report and review of the literature

Schuermans, C., Bergen, M. V., Coorevits, L., Verhaegen, J., Lagrou, K., Surmont, I., & Jeurissen, A. (2010) · Medical Mycology · doi:10.3109/13693786.2010.535179 · Cited by 60

Development and Validation of a Quantitative PCR Assay for Diagnosis of Scedosporiosis

Castelli, M. V., Buitrago, M. J., Bernal‐Martínez, L., Gómez‐López, A., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00046-08 · Cited by 59

Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

Rueda, C., Puig-Asensio, M., Guinea, J., Almirante, B., Cuenca-Estrella, M., Zaragoza, O., Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J. R., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.016 · Cited by 58

Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B

Smith, P. J., Olson, J. A., Constable, D., Schwartz, J., Proffitt, R. T., & Adler‐Moore, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm077 · Cited by 58

Biofilm Formation and Resistance to Fungicides in Clinically Relevant Members of the Fungal Genus Fusarium

Sav, H., Rafati, H., Öz, Y., Cılo, B. D., Ener, B., Mohammadi, F., İlkit, M., van Diepeningen, A., & Seyedmousavi, S. (2018) · Journal of Fungi · doi:10.3390/jof4010016 · Cited by 60

Update on the treatment of disseminated fusariosis: Focus on voriconazole.

Stanzani, M., Tumietto, F., Vianelli, N., & Baccarani, M. (2007) · PubMed Central · Cited by 58

Phaeohyphomycosis due to Alternaria species in transplant recipients

Boyce, R., Deziel, P. J., Otley, C. C., Wilhelm, M. P., Eid, A. J., Wengenack, N. L., & Razonable, R. R. (2009) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2009.00482.x · Cited by 57

The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agentsin vitro

Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.2 · Cited by 56

Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature

Schooneveld, T. C. V., Freifeld, A. G., Lesiak, B., Kalil, A. C., Sutton, D. A., & Iwen, P. C. (2007) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2007.00248.x · Cited by 57

A new model of in vitro fungal biofilms formed on human nail fragments allows reliable testing of laser and light therapies against onychomycosis

Vila, T. V. M., Rozental, S., & Guimarães, C. M. D. D. S. (2014) · Lasers in Medical Science · doi:10.1007/s10103-014-1689-y · Cited by 57

Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi‐centre study

Schmalreck, A., Willinger, B., Haase, G., Blum, G., Lass‐Flörl, C., Fegeler, W., Becker, K., & for the Antifungal Susceptibility Testing (AFST) Study Group (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02165.x · Cited by 57

Azole‐resistant Candida spp. – emerging pathogens?

Tobudic, S., Kratzer, C., & Presterl, E. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02146.x · Cited by 57

Fungal Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patients

Bays, D. J., & Thompson, G. R. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.02.006 · Cited by 56

Developments in the treatment of candidiasis: more choices and new challenges

Aperis, G., Myriounis, N., Spanakis, E. K., & Mylonakis, E. E. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.11.1319 · Cited by 57

Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program

Pfaller, M. A., Messer, S. A., Boyken, L. B., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01952-07 · Cited by 55

Carbon Assimilation Profiles as a Tool for Identification of Zygomycetes

Schwarz, P., Lortholary, O., Dromer, F., & Dannaoui, É. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02219-06 · Cited by 54

Novel antifungal agents: a patent review (2013 - present)

Castelli, M. V., Derita, M., & López, S. N. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1261113 · Cited by 53

Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds

Cuenca‐Estrella, M., Gómez‐López, A., Mellado, E., Monzón, A., Buitrago, M. J., & Rodrı́guez-Tudela, J. L. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01543-08 · Cited by 53

Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran

Szigeti, G., Sedaghati, E., Mahmoudabadi, A. Z., Naseri, A., Kocsubé́, S., Vágvölgyi, C., & Varga, J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02103.x · Cited by 51

Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999–2008

Playford, E. G., Nimmo, G. R., Tilse, M. H., & Sorrell, T. C. (2010) · Journal of Hospital Infection · doi:10.1016/j.jhin.2010.01.022 · Cited by 50

Airborne transmission of invasive fusariosis in patients with hematologic malignancies

Moretti, M. L., Busso-Lopes, A. F., Tararam, C. A., Moraes, R., Muraosa, Y., Mikami, Y., Gonoi, T., Taguchi, H., Lyra, L., Reichert‐Lima, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196426 · Cited by 50

Angioinvasive fungal infections impacting the skin

Berger, A. P., Ford, B. A., Brown‐Joel, Z. O., Shields, B. E., Rosenbach, M. A., & Wanat, K. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.058 · Cited by 49

Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006

Dannaoui, É., Lortholary, O., Raoux‐Barbot, D., Bougnoux, M., Galeazzi, G. M., Lawrence, C., Moissenet, D., Poilane, I., Hoinard, D., & Dromer, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01140-07 · Cited by 49

Evaluation of Oral Itraconazole Administration in Captive Humboldt Penguins (Spheniscus humboldti)

Bunting, E. M., Abou‐Madi, N., COX, S. K., Martín‐Jiménez, T., Fox, H., & Kollias, G. V. (2009) · Journal of Zoo and Wildlife Medicine · doi:10.1638/2009-0045.1 · Cited by 48

A case series of unilateral orbital aspergillosis in three cats and treatment with voriconazole

Smith, L. N., & Hoffman, S. B. (2010) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2010.00780.x · Cited by 47

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother

Cuenca-estrella, M., Gomez-lopez, A., Mellado, E., Buitrago, M. J., Monzón, A., & Rodriguez-tudela, J. L. (2006)

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00163-06 · Cited by 491

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

Carrillo-Muñoz, A.-J., Quindós, G., Ruesga, M., Alonso, R., del Valle, O., Hernández-Molina, J. M., McNicholas, P. M., Loebenberg, D., & Santos, P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki022 · Cited by 31

1148. Activity of Posaconazole and Comparator Antifungal agents Tested Against Filamentous Fungi

Castanheira, M., Carvalhaes, C. G., Motyl, M. R., Han, S., & Campbell, H. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa439.1334

In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans

Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 144